4basebio Plc - Synthetic opDNA® utilised in Phase I/II US clinical trials
4basebio PLC
("4basebio" or the "Company")
SyntheticopDNA®utilised in Phase I/II US clinical trials
Global pharma partner initiates mRNA therapy trial using 4basebio’s opDNA® template, marking a key milestone in synthetic DNA adoption for advanced genetic medicines
, - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products announces that, following Investigational New Drug (IND) approval from the FDA, a global Tier 1 pharmaceutical partner has begun dosing patients with an mRNA product developed using 4basebio’s proprietary opDNA® template. The Company signed the supply agreement with the partner in . Specific details of the clinical trial are not able to be disclosed at this time due to innovator confidentiality.
The opDNA® template, one of four application-specific DNA templates developed by 4basebio, supports mRNA invitro transcription (IVT) processes and offers significant cost, purity and timeline advantages against the incumbent plasmid DNA.
These clinical achievements follows 4basebio receiving the GMP certification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) of its late-phase manufacturing facility in . These accomplishments underscore 4basebio’s role as a trusted partner to the global biopharma industry, delivering high-quality synthetic DNA to power next-generation therapies.
Synthetic DNA represents a fundamental shift for the life sciences sector. Unlike traditional plasmid DNA, which is constrained by lengthy manufacturing timelines and contamination risks, 4basebio’s proprietary technology platform enables faster, scalable, and cell-free production of DNA templates. This technology advancement not only accelerates the development timelines for cell & gene therapies and vaccines but also offers superior safety and consistency, two critical factors for clinical success.
By removing bottlenecks in DNA supply, 4basebio enables researchers and drug development innovator companies to bring transformative therapies to patients more quickly and more safely, with the potential to change lives across infectious disease, oncology, and rare genetic disorders.
Dr. , 4basebio CEO, commented
“We are excited to see increasing momentum as a growing number of client programs advance into the clinic.”
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.
For further enquiries, please contact:
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
4basebio PLC +44 (0)12 2396 7943 Dr. , CEO Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880 / / Ed Downes Cavendish Capital Markets Limited (JointBroker) +44 (0)20 7220 0500 / RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000 /Heikki Lanckriet Jo Turner Sandy Jamieson Geoff Nash Nigel Birks Kathryn Deegan Matthew Coakes

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE